A Pill That Nearly Doubles Survival in Pancreatic Cancer: The Daraxonrasib Breakthrough

A Pill That Nearly Doubles Survival in Pancreatic Cancer: The Daraxonrasib Breakthrough

1. The Study at a Glance

In May 2026 researchers presented results from a Phase III clinical trial of daraxonrasib an experimental pill for advanced pancreatic cancer at the American Society of Clinical Oncology meeting in Chicago. Published simultaneously in the New England Journal of Medicine the trial randomized 500 patients with advanced pancreatic cancer to either daily daraxonrasib pills or standard intravenous chemotherapy. The results stunned the room: patients on daraxonrasib lived a median of 13 months nearly double the 6.7 months for those on chemotherapy. Seventeen percent of patients were still alive after two years compared with 7 percent on chemo.

2. The Numbers in Context

Pancreatic cancer is notoriously lethal. Only 3 percent of patients with advanced disease survive five years and diagnosis typically comes late after the cancer has already spread beyond the pancreas. Conventional chemotherapy buys most patients less than a year. So a pill that adds six months of life and does so with fewer severe side effects is genuinely practice-changing. Only 1 percent of daraxonrasib patients stopped treatment due to side effects versus 11 percent on chemo. The most common severe issue was a rash affecting about 14 percent of patients manageable with topical creams and oral medications.

3. How It Works: The Molecular Glue

The science is what makes this truly remarkable. Pancreatic cancer is commonly driven by malfunctioning RAS proteins tiny molecular switches that get stuck in the 'on' position and relentlessly signal cells to grow. For four decades RAS was considered 'undruggable' because its surface is smooth as a ball bearing with no obvious pockets for a drug to latch onto. Daraxonrasib sidesteps this problem with an elegant workaround. The pill first binds to cyclophilin A a protein abundant in human cells. This pair then clamps onto RAS together blocking its growth signals. Researchers describe it as 'an embrace of death' the drug and its partner bear-hugging the cancer-driving protein into submission.

4. The Caveats

Experts are careful not to oversell this. 'This is not a panacea' said pancreatic cancer researcher Anirban Maitra. 'We have not cured pancreas cancer.' The drug has not yet received FDA approval though the manufacturer has been permitted to expand access for seriously ill patients with no other options. The rash side effect is nearly universal about 90 percent of patients develop some form of skin reaction and while manageable it's something clinicians will need to learn to handle as the drug enters wider use.

5. What It Means

This is the first targeted therapy to show a meaningful survival benefit in pancreatic cancer a disease where virtually every previous drug candidate has failed. The 'molecular glue' mechanism opens a whole new avenue for drug design potentially targeting other RAS-driven cancers like lung and colorectal that have also defied treatment. Dana-Farber's Brian Wolpin who presented the results summed up the moment: 'Let's all get to work. Let's figure this out.'

6. Bottom Line

Daraxonrasib nearly doubled survival in advanced pancreatic cancer compared to chemotherapy with significantly fewer severe side effects using a novel 'molecular glue' mechanism that finally cracks the undruggable RAS protein. It's not a cure but it's the first real breakthrough in one of medicine's toughest cancers.

Source: New England Journal of Medicine ASCO 2026 Wolpin et al. DOI: 10.1056/NEJMoa2605555 Phase III RCT N=500